Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma

SIMPLE SUMMARY: Predictive markers are necessary for immune checkpoint inhibitor (ICI) therapy. The aim of our retrospective study was to investigate the relationship between the occurrence of lymphopenia under ICI and disease outcome. A total of 116 patients with metastatic melanoma who received IC...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomsitz, Dirk, Schlaak, Max, Zierold, Sarah, Pesch, Giulia, Schulz, Thomas U., Müller, Genoveva, Zecha, Christine, French, Lars E., Heinzerling, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265779/
https://www.ncbi.nlm.nih.gov/pubmed/35805052
http://dx.doi.org/10.3390/cancers14133282

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265779/
https://www.ncbi.nlm.nih.gov/pubmed/35805052
http://dx.doi.org/10.3390/cancers14133282

Ejemplares similares